MiRNA therapy targeting cancer stem cells: A new paradigm for cancer treatment and prevention of tumor recurrence

Therapeutic Delivery

Volumn 6, Issue 3, 2015, Pages 323-337

  Osaki, Mitsuhiko ^a,b   Okada, Futoshi ^a,b   Ochiya, Takahiro ^c  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; VIRUS VECTOR;

BRAIN TUMOR; BREAST CANCER; CANCER STEM CELL; CANCER THERAPY; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; HUMAN; IN VIVO STUDY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR RECURRENCE; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS;

DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84927614129     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.122     Document Type: Review

References (159)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA. Cancer J. Clin. 61(2), 69-90 (2011).
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
3. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
4. Alison MR, Islam S, Wright NA. Stem cells in cancer: instigators and propagators? J. Cell Sci. 123, 2357-2368 (2010).
5. Friedman GK, Gillespie GY. Cancer stem cells and pediatric solid tumors. Cancer 3, 298-318 (2011).
6. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 124, 1111-1115 (2006).
7. Greaves M. Cancer stem cells: back to Darwin? Semin. Cancer Biol. 20, 65-70 (2010).
8. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N. Engl. J. Med. 355, 1253-1261 (2006).
9. Cohnheim J. Congenitales, quergestreiftes Muskelsarkon der Nireren. Virchows Arch. 65, 64-69 (1875).
10. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66, 1883-1890 (2006).
11. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implication in breast cancer. J. Mammary Gland Biol. Neoplasia. 15(2), 253-260 (2010).
12. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J. Clin. Oncol. 26(17), 2806-2812 (2008).
13. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997).
14. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828 (2003).
15. Singh SK, Hawkins C, Phylogenies TF, Compare EP. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
16. Mao XG, Zhang X, Xue XY et al. Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl. Oncol. 2, 247-257 (2009).
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
18. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007).
19. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110 (2007).
20. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer initiating cells. Nature 445, 111-115 (2007).
21. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158-10163 (2007).
22. Meng E, Long B, Sullivan P et al. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin. Exp. Metastasis 29, 939-948 (2012).
23. Ferrandina G, Bonanno G, Pierelli L et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int. J. Gynecol. Cancer 18 506-514 (2008).
24. Luo L, Zeng J, Liang B et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp. Mol. Pathol. 91, 596-602 (2011).
25. Collins AT, Berry PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951 (2005).
26. Kim CFB, Jackson EL, Woolfenden AE et al. Identification of bronchioalveolar stem cells normal lung and lung cancer. Cell 121, 823-835 (2005).
27. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504-514 (2008).
28. Takaishi S, Okumura T, Tu S et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006-1020 (2009).
29. Yamashita T, Honda M, Nio K et al. Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. Cancer Res. 70, 4687-4697 (2010).
30. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007).
31. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339-9344 (2006).
32. Bauerschmitz GJ, Ranki T, Kangasniemi L et al. Tissuespecific promoter active in CD44+CD24-/low breast cancer cells. Cancer Res. 68(14), 5533-5539 (2008).
33. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J. Clin. Oncol. 26, 2806-2812 (2008).
34. Chen KL, Pan F, Jiang H et al. Highly enriched CD133(+) CD44(+) stem-like cells with CD133(+) CD44(high) metastatic subset in -hCT116 colon cancer cells. Clin. Exp. Metastasis 28(8), 751-763 (2011).
35. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367, 645-648 (1994).
36. Colmont CS, Harding KG, Piguet V, Patel GK. Human skin cancer stem cells: a tale of mice and men. Exp. Dermatol. 21, 576-580 (2012).
37. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 14(3), 275-291 (2014).
38. Chen T, Dent SYR. Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat. Rev. Genet. 15(2), 93-106 (2014).
39. Sun L, Mathews LA, Cabarcas SM et al. Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells 31(8), 1454-1466 (2013).
40. Suvà ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 339(6127), 1567-1570 (2013).
41. Wend P, Fang L, Zhu Q et al. Wnt/β-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours. EMBO J. 32(14), 1977-1989 (2013).
42. Jamieson CH, Ailles LE, Dylla SJ et al. Granulocytemacrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667 (2004).
43. Korkaya H, Paulson A, Charafe-Jauffret E et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/betacatenin signaling. PLoS Biol. 7(6), e1000121 (2009).
44. Hoey T, Yen WC, Axelrod F et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177 (2009).
45. Taketo MM. Reflections on the spread of metastasis to cancer prevention. Cancer Prev. Res. 4, 324-328 (2011).
46. Liu S, Dontu G, Mantle ID et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66(12), 6063-6071 (2006).
47. Varnat F, Duquet A, Malerba M et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signaling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 1, 338-351 (2009).
48. Takezaki T Hide T, Takanaga H, Nakamura H, Kuratsu J, Kondo T. Essential role of the Hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci. 102, 1306-1312 (2011).
49. Nimmo RA, Slack FJ. An elegant mirror: microRNAs in stem cells, developmental timing and cancer. Chromosoma 118(4), 405-418 (2009).
50. Liu B, Sun L, Song E. Non-coding RNAs regulate tumor cell plasticity. Sci. China Life Sci. 56(10), 886-890 (2013).
51. Bartel DP. Micro RNAs: Genomics biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
52. Stefani G, Slack FJ. Small noncoding RNAs in animal development. Nat. Rev. Mol. Cell Biol. 9, 219-230 (2008).
53. Denli AM, Tops BBJ, Plasterk RHA, Ketting REF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature 432, 231-235 (2004).
54. Gregory RI, Yan KP, Amuthan G et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 432, 235-240 (2004).
55. Hutvágner G, Zamore PD. A microRNA in a multipleturnover RNAi enzyme complex. Science 297, 2056-2030 (2002).
56. Hammond SM. Dicing and slicing: The core machinery of the RNA interference pathway. FEBS Lett. 579(26), 5822-5829 (2005).
57. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123, 631-640 (2005).
58. Eini R, Dorssers LCJ, Looijenga LHJ. Role of stem cell proteins and microRNAs in embryogenesis and germ cell cancer. Int. J. Dev. Biol. 57, 319-332 (2013).
59. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993).
60. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in C. elegans. Science 294, 858-862 (2001).
61. miRBase: the miRNA database www.mirbase.org
62. Bentwich I, Avniel A, Karov Y et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet. 37, 766-770 (2005)
63. Lagos-Quintana M, Rauhut R, Meyer J et al. New microRNAs from mouse and human. RNA 9, 175-179 (2003).
64. Bernstein E, Kim SY, Carmell MA et al. Dicer is essential for mouse development. Nat. Genet. 35, 215-217 (2003).
65. Kanellopoulou C, Muljo SA, Kung AL et al. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev. 19, 489-501 (2005).
66. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat. Genet. 39, 380-385 (2007).
67. Choi YJ, Lin CP, Ho JJ et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat. Cell Biol. 13, 1353-1360 (2011).
68. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917-1920 (2007).
69. Guessous F, Zhang Y, Kofman A et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 9, 1031-1036 (2010).
70. Godlewski J, Nowicki MO, Bronisz A et al. Micro RNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620-632 (2010).
71. Silber J, Lim DA, Petritsch C et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 6, 14 (2008).
72. Godlewski J, Nowicki MO, Bronisz A et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 68, 9125-9130 (2008).
73. Garzia L, Andolfo I, Cusanelli E et al. Micro RNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS ONE 4, e4998 (2009).
74. Gal H, Pandi G, Kanner AA et al. MIR-451 and imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem. Biophys. Res. Commun. 376, 86-90 (2008).
75. Johansson J, Berg T, Kurzejamska E et al. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene 32(50), 5614-5624 (2013).
76. Huang S, Chen L. miR-888 regulates side population properties and cancer metastasis in breast cancer cells. Biochem. Biophys. Res. Commun. 450, 1234-1240 (2014).
77. Yu F, Yao H, Zhu P et al. Let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 (2007).
78. Zhang H, Cai K, Wang J et al. MiR-7, inhibited indirectly by LincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells 32 (11), 2858-2868 (2014 ).
79. Shimono Y, Zabala M, Cho RW et al. Downregulation of miR-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
80. Yu Y, Kanwar SS, Patel BB et al. Micro RNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis 33, 68-76 (2012).
81. Song B, Wang Y, Xi Y et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28, 4065-4074 (2009).
82. Nicolas FE, Pais H, Schwach F et al. Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140. RNA 14, 2513-2520 (2008).
83. Song B, Wang Y, Titmus MA et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol. Cancer 9, 96 (2010).
84. Bu P, Chen KY, Chen JH et al. A microRNA-34a-regulated bimodal switch targets notch in colon cancer stem cells. Cell Stem Cell 12, 602-615 (2013).
85. Yu XF, Zou J, Bao ZJ, Dong J. miR-93 suppresses proliferation and colony formation of human colon cancer stem cells. World J. Gastroenterol. 17, 4711-4717 (2011).
86. Xu XT, Xu Q, Tong JL et al. Micro RNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br. J. Cancer 106, 1320-1330 (2012).
87. Bitarte N, Bandres E, Boni V et al. Micro RNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29, 1661-1671 (2011).
88. Xu CX, Xu M, Tan L et al. microRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J. Biol. Chem. 287(42), 34970-34978 (2012).
89. Cheng W, Liu T, Wan X, Gao Y, Wang H. Micro RNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J. 279, 2047-2059 (2012).
90. Wang Z, Ting Z, Li Y, Chen G, Lu Y, Hao X. microRNA- 199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol. Lett. 6(3), 789-794 (2013).
91. Wu Q, Guo R, Lin M, Zhou B, Wang Y. microRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol. Oncol. 122(1), 149-154 (2011).
92. Liu C, Kelnar K, Liu B et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 17, 211-215 (2011).
93. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y, Sarkar FH. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am. J. Transl. Res. 4, 432-442 (2012).
94. Li K, Liu C, Zhou B et al. Role of EZH2 in the Growth of Prostate Cancer Stem Cells Isolated from LNCaP Cells. Int. J. Mol. Sci. 14(6), 11981-11993 (2013).
95. Jin M, Zhang T, Liu C et al. miRNA-128 Suppresses Prostate Cancer by Inhibiting BMI-1 to Inhibit Tumor-Initiating Cells. Cancer Res. 74(15), 4183-4195 (2014).
96. Hsieh IS, Chang KC, Tsai YT et al. Micro RNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis 34(3), 530-538 (2013).
97. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2, 552-560 (2001).
98. Ostrom QT, Gittleman H, Farah P et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro. Oncol. 15, ii1-ii56 (2013).
99. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 379, 1984-1996 (2012).
100. Miraglia S, Godfrey W, Yin A et al. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90, 5013-5021 (1997).
101. Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-5012 (1997).
102. Yu L, Baxter PA, Voicu H et al. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro. Oncol. 12, 580-594 (2010).
103. Li Y, Guessous F, Zhang Y et al. Micro RNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69, 7569-7576 (2009).
104. Li KKW, Pang JC, Ching AK et al. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum. Pathol. 40, 1234-1243 (2009).
105. Xia H, Cheung WKC, Ng SS et al. Loss of brain-enriched miR-124 microRNA enhances stem-like traits and invasiveness of glioma cells. J. Biol. Chem. 287, 9962-9971 (2012).
106. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007).
107. Prud'homme GJ. Cancer stem cells and novel targets for antitumor strategies. Curr. Pharm. Des. 18, 2838-2849 (2012).
108. Okuda H, Xing F, Pandey PR et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res. 73, 1434-1444 (2013).
109. Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008).
110. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 22, 894-907 (2008).
111. Kong W, Yang H, He L et al. Micro RNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 28(22), 6773-6784 (2008).
112. Ma L, Young J, Prabhala H et al. miR-9, aMYC/MYCNactivated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12(3), 247-256 (2010).
113. Gwak JM, Kim HJ, Kim EJ et al. Micro RNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res. Treat. 147(1), 39-49 (2014).
114. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69, 3382-3389 (2009).
115. Lengyel E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053-1064 (2010).
116. Klonisch T, Wiechec E, Hombach-Klonisch S et al. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 14(10), 450-460 (2008).
117. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
118. Golebiewska A, Brons NHC, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 8(2), 136-147 (2011).
119. Xu XT, Xu Q, Tong JL et al. Micro RNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br. J. Cancer 106(7), 1320-1330 (2012).
120. Bitarte N, Bandres E, Boni V et al. Micro RNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29, 1661-1671 (2011).
121. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanism. Int. J. Oncol. 23, 17-28 (2003).
122. Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Ochiya T. Stilbene derivatives promote Ago-2- dependent tumour-suppressive microRNA activity. Sci. Rep. 2, 314 (2012).
123. Yang F, Nam S, Brown CE et al. A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via upregulation of miRNA-4284 and JNK/AP-1 signaling. PLoS ONE 9(4), e94443 (2014).
124. Bao B, Ali S, Ahmad A et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS ONE 7(12), e50165 (2012).
125. Ono M, Kosaka N, Tominaga N et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci. Signal. 7(332), ra63 (2014).
126. Rombouts K, Carloni V, Mello T et al. Myristoylated alanine-rich protein kinase C substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo. Cancer Lett. 333, 244-252 (2013).
127. Zhu S, Pan W, Song X et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-a. Nat. Med. 18, 1077-1086 (2012).
128. Pihlmann M, Askou AL, Aagaard L et al. Adeno-associated virus-delivered polycistronic microRNA-clusters for knockdown of vascular endothelial growth factor in vivo. J. Gene Med. 14, 328-338 (2012).
129. Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53- induced mouse model of lung adenocarcinoma. Cancer Res. 72, 5576-5587 (2012).
130. Pfeifer A, Verma IM. Gene therapy: promises and problems. Annu. Rev. Genomics Hum. Genet. 2, 177-211 (2001).
131. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346-358 (2003).
132. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr. Gene Ther. 4, 357-372 (2004).
133. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer. Adv. Drug Deliv. Rev. 65, 1866-1879 (2013).
134. SØrensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic sirnas in adult mice. J. Mol. Biol. 327, 761-766 (2003).
135. Verma UN, Surabhi RM, Schmaltieg A, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against b-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9, 1291-1300 (2003).
136. Yano J, Hirabayashi K, Nakagawa S-I et al. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10, 7721-7726 (2004).
137. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461-466 (2005).
138. Xu D, Takeshita F, Hino Y et al. miR-22 represses cancer progression by inducing cellular senescence. J. Cell Biol. 193(2), 409-424 (2011).
139. Civenni G, Malek A, Albino D et al. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res. 73(22), 6816-6827 (2013).
140. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl Acad. Sci. USA 104, 2-7 (2007).
141. Minakuchi Y, Takeshita F, Kosaka N et al. Atelocollagenmediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 32, e109 (2004).
142. Takeshita F, Minakuchi Y, Nagahara S et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl Acad. Sci. USA 102, 12177-12182 (2005).
143. Takeshita F, Patrawala L, Osaki M et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18, 181-187 (2010).
144. Osaki M, Takeshita F, Sugimoto Y et al. Micro RNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol. Ther. 19(6), 1123-1130 (2011).
145. Al-jamal KT, Gherardini L, Bardi G, Nunes A, Guo C, Bussy C. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc. Natl Acad. Sci. USA 108, 10952-10957 (2011).
146. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101(10), 2087-2092 (2010).
147. Weber JA, Baxter DH, Zhang S et al. The microRNA spectrum in 12 body fluids. Clin. Chem. 56(11), 1733-1741 (2010).
148. Kosaka N, Izumi H, Sekine K, Ochiya T. microRNA as a new immune-regulatory agent in breast milk. Silence 1(1), 7 (2010).
149. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105(30), 10513-10518 (2008).
150. Park NJ, Zhou H, Elashoff D et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15(17), 5473-5477 (2009).
151. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007).
152. Zitvogel L, Regnault A, Lozier A et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nat. Med. 4(5), 594-600 (1998).
153. Van Niel G, Raposo G, Candalh C et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 121(2), 337-349 (2001).
154. Wolfers J, Lozier A, Raposo G et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 7(3), 297-303 (2001).
155. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL. Functional delivery of viral miRNAs via exosomes. Proc. Natl Acad. Sci. USA 107(14), 6328-6333 (2010).
156. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 39(1), 133-144 (2010).
157. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 285(23), 17442-17452 (2010).
158. Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J. Biol. Chem. 287(2), 1397-1405 (2012).
159. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21(1), 185-191 (2013).